Clinical trials on Solid Tumors

  • CT-EU-00117038


    This is a Phase 1/2 clinical trial looking at a new investigational drug called CFT1946 for treating certain types of solid tumors that have a specific genetic mutation called BRAF V600. This includes cancers like melanoma, non-small cell lung cancer, colorectal cancer, and a type of thyroid cancer called anaplastic thyroid cancer.

    In the first part of the study, called Phase 1, the main goals are to determine the highest safe dose of CFT1946 that can be given and to look at side effects. CFT1946 will be given by itself (monotherapy) or combined with two other approved drugs, trametinib or cetuximab.

    If safe doses are found in Phase 1, the study will then move to Phase 2. In this part, the main goals are to see if the treatments shrink tumors, measured by overall response rate and disease control rate, and how long any responses last, called duration of response.

    The study involves taking CFT1946 and possibly the other drugs by mouth or intravenously on a set schedule, along with regular monitoring, scans, and blood tests. Participation could last up to around 43 months.

    • CFT1946
    • Trametinib
    • Cetuximab
  • Evaluating Idasanutlin in Combination Therapy for Young Patients with Leukemia or Solid Tumors

    This clinical trial is an important study that aims to find out how safe and effective a new treatment called Idasanutlin is when used alone or in combination with either chemotherapy or a medication named Venetoclax. This study is specifically for children and young adults who have certain types of cancer that have not responded to previous treatments. These cancers include Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, and other solid tumors.

    The study is organized into three parts. The first part will focus on finding the highest dose of Idasanutlin that can be given safely to patients with solid tumors. After that, the study will look at how well Idasanutlin works in combination with chemotherapy or Venetoclax in patients with neuroblastoma, AML, and ALL. The goal is to determine the best dose of Idasanutlin to use in these combinations. In the second part of the study, new patients will be treated with these combinations to further evaluate their safety and how effective they are. There might be a third part to the study, which would allow even more patients to receive these treatments, providing more information on their safety and effectiveness.

    Idasanutlin will be taken orally once a day for the first 5 days of a 28-day cycle. Venetoclax’s dose will depend on the type of cancer being treated and will also be taken orally. The chemotherapy drugs used in the study include Cyclophosphamide, Topotecan, Fludarabine, and Cytarabine, which are given through an IV. Additionally, patients with leukemia will receive intrathecal chemotherapy to treat cancer cells in the spinal fluid.

    The main things the study will look at are how many patients experience side effects and how severe those side effects are, how many patients have serious side effects from the treatment, and how well the treatment works against the cancer. This includes looking at how many patients with neuroblastoma respond to the treatment, how many patients with leukemia achieve complete remission, and how many patients with ALL have no detectable cancer cells after treatment.

    This study is a chance for patients who have not had success with other treatments to try a new approach that could potentially be more effective. It’s also an opportunity to contribute to medical research that could help future patients with similar conditions.

    • cytarabine
    • Intrathecal Chemotherapy
    • Idasanutlin
    • Fludarabine
    • topotecan
    • Cyclophosphamide
    • Venetoclax